Crossmark

Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?

Crossref DOI link: https://doi.org/10.1038/s41408-023-00819-5

Published Online: 2023-04-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Sining https://orcid.org/0000-0002-9744-2598
Zhang, Xinyue https://orcid.org/0000-0002-2100-0152
Dai, Haiping

Cui, Wei

Yin, Jia https://orcid.org/0000-0002-4228-406X
Li, Zheng https://orcid.org/0000-0002-9046-4612
Yang, Xiao

Yang, Chunxiu

Xue, Shengli https://orcid.org/0000-0003-4609-616X
Qiu, Huiying

Miao, Miao https://orcid.org/0000-0002-3435-9498
Chen, Suning

Jin, Zhengming

Fu, Chengcheng

Li, Caixia

Sun, Aining

Han, Yue https://orcid.org/0000-0002-7560-7195
Wang, Ying

Yu, Lei

Wu, Depei https://orcid.org/0000-0002-6312-3863
Cui, Qingya https://orcid.org/0000-0002-5067-5650
Tang, Xiaowen https://orcid.org/0000-0003-1766-7891
License Information

Text and Data Mining valid from 2023-04-24

Version of Record valid from 2023-04-24
More Information

Article History

Received: 28 November 2022

Revised: 9 March 2023

Accepted: 15 March 2023

First Online: 24 April 2023

Competing interests

: The authors declare no competing interests.